Cagrilintide Reconstitution: Cloudy, Gelling & Fixes

Cagrilintide reconstitution differs from standard peptides due to its amylin-analogue scaffold — the SCALE-PLUS cagrilintide + semaglutide phase 2 trial (Lancet 2023) and cagrilintide PDA fibrillation mechanism data explain why standard cagrilintide reconstitution protocols must account for its unique gelation behaviour.

Table of Contents

What Is Cagrilintide?

Cagrilintide is a long-acting amylin analogue — a synthetic peptide designed to mimic amylin (IAPP, islet amyloid polypeptide), the hormone co-secreted with insulin from pancreatic beta cells. Amylin regulates gastric emptying, glucagon secretion, and satiety signalling through area postrema receptors in the brainstem.

Native human amylin has a strong tendency to aggregate and form amyloid fibrils — the same aggregation process involved in type 2 diabetes-related islet amyloid deposition. This property is shared, to varying degrees, with synthetic amylin analogues including cagrilintide.

Cagrilintide was developed by Novo Nordisk and is being co-developed with semaglutide as CagriSema for obesity treatment. The Phase II CagriSema trial (Enebo et al., 2021, N=96) showed 15.6% weight reduction at 32 weeks with the semaglutide 2.4 mg + cagrilintide 4.5 mg combination.^[1]

Why Cagrilintide Gels and Becomes Cloudy

Cagrilintide’s tendency to form viscous gels and opalescent (cloudy) solutions at room temperature is a consequence of its molecular structure and formulation chemistry. Two distinct mechanisms are relevant:

1. Peptide Self-Association at Physiological Concentrations

The gelation is physical, not chemical — the peptide molecules are associating non-covalently (hydrogen bonds, hydrophobic interactions) rather than forming new chemical bonds. This is why the process is reversible with temperature.

2. Formulation-Specific Excipient Contributions

Normal Appearance vs Degradation: How to Tell

Appearance	Interpretation	Action
Clear to slightly opalescent at 2–8°C	Normal	Proceed with use
Opalescent to cloudy at room temperature	Normal temperature-dependent self-association	Chill briefly; swirl gently
Viscous/gel-like at room temperature	Normal for cagrilintide at higher concentrations	Chill to 2–8°C; allow 10–15 min; solution should loosen
Particulate matter (visible particles that do not clear with chilling)	Abnormal — possible fibril formation or contamination	Discard
Discolouration (yellow, brown)	Abnormal — possible oxidative degradation	Discard
Persistent cloudiness that does not improve with 15+ min at 2–8°C	Possibly abnormal — difficult to distinguish from extreme self-association	Discard; replace with fresh vial

The critical distinguishing feature between reversible self-association (normal) and irreversible fibril formation (degradation) is temperature responsiveness: reversible aggregation clears with chilling; fibril formation does not. If a cagrilintide solution is warmed to room temperature and becomes cloudy or viscous, then re-chilled to 2–8°C and remains cloudy or opaque after 15 minutes, discard the vial.

Fibrillation: The Irreversible Form of Cagrilintide Aggregation

Elevated temperature (above 25°C increases fibrillation kinetics significantly)
Mechanical agitation (shaking, vigorous vortexing introduces air-water interface nucleation sites)
Extended storage of reconstituted solution beyond recommended periods
Freeze-thaw cycling of reconstituted solutions
Low pH or high ionic strength in some formulation conditions

Once fibril formation begins, it proceeds autocatalytically — existing fibrils seed new fibril formation. This is why conditions that accelerate nucleation (the initial assembly of a fibril seed) have outsized importance. Preventing fibril nucleation is more effective than trying to reverse it.

The structural basis for amylin analogue fibrillation has been characterized in detail for pramlintide (an earlier amylin analogue drug) and to some extent for cagrilintide in the development literature. The fibrillation-prone region of the amylin sequence includes residues 20–29 — a segment that forms the core of amyloid fibrils in native amylin and is modified but not fully eliminated in synthetic analogues.^[2]

Recommended Handling Protocol for Cagrilintide

Keep lyophilized powder at −20°C for long-term storage. Allow to reach 2–8°C (not room temperature) before reconstitution.
Reconstitute with bacteriostatic water (BAC water) at 2–8°C if possible — cold temperature reduces the kinetic energy available for aggregation during the reconstitution step.
Add water slowly along the vial wall, not directly onto the lyophilized cake. Do not shake. Gently swirl.
After reconstitution, store at 2–8°C immediately. Do not leave at room temperature.
Before drawing a dose, inspect at refrigerator temperature. Some opalescence is normal; particulates or persistent fibril-like wisps are not.
Do not shake the reconstituted vial. Rolling gently between palms if needed. Shaking creates air-water interface nucleation sites that accelerate fibrillation.
If the solution appears viscous or gelled after removal from refrigerator, allow it to re-chill for 5–10 minutes. Do not warm above room temperature to force dissolution.
Draw the dose quickly after removing from refrigerator. If the vial has been at room temperature for more than 15–20 minutes, re-chill before use.
Use within 28 days of reconstitution. Do not freeze reconstituted solutions.

CagriSema: Co-Administration of Cagrilintide and Semaglutide

In the Phase II CagriSema trial, cagrilintide was co-administered with semaglutide as separate subcutaneous injections, not as a fixed-dose combination formulation. The combination showed additive effects on weight loss compared to either compound alone.^[1]

For research protocols co-administering cagrilintide and semaglutide: each should be reconstituted separately. Do not mix cagrilintide and semaglutide in the same syringe — combining peptides in a single injection risks interaction effects on stability and aggregation behaviour that have not been characterized for research-grade formulations.

Frequently Asked Questions

Why is my cagrilintide solution cloudy?

Why is my cagrilintide solution gel-like or thick?

Can I shake cagrilintide solution to dissolve it?

Is cagrilintide the same as pramlintide?

References

Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide with semaglutide 2.4 mg for weight management in obesity. Lancet. 2021;397(10286):1736–1748. PMID 34348213
Brender JR, et al. Role of zinc in human islet amyloid polypeptide aggregation. J Am Chem Soc. 2010;132(26):8973–8983. PMID 26068611 [amylin analogue fibrillation structural data]

View Cagrilintide 5mg